🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareWeekly check-in thread — March 10–16, 2026 Page 2

Weekly check-in thread — March 10–16, 2026

mike_mod Sun, May 31, 2026 at 8:46 PM 7 replies 337 viewsPage 2 of 2
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jun 1, 2026 at 2:50 AM#6
kate.chem said:
Relative and absolute effects need reading together.

I read this differently from kate.chem, on substance rather than tone. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

Happy to go further on any of that.

Last edited: Jun 1, 2026 at 3:50 AM
37 7maya_sedona, stefan_berlin, Dr.EM_Chicago and 34 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Jun 1, 2026 at 5:13 AM#7
mike_mod said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.73 (95% CI 0.68-0.83), I²=31%. This is a robust and consistent effect.

36 6Dr.GutHealth, amsterdam_pete, LondonLisa and 33 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jun 1, 2026 at 7:36 AM#8
BethLabQueen said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced stroke risk (HR 0.82) over 4 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
35 5AussieAnna, BethLabQueen, ChrisMacros and 32 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
ChrisMacros
Member
567
2,345
Sep 2024
Michigan
Jun 1, 2026 at 9:59 AM#9

One thing that is still open after SarahChen_PharmD’s answer:

What would you measure differently if you were starting again?

34 4LibrarianMeg, bri_stats, pete_manc_UK and 31 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 1, 2026 at 9:24 PM#10

Reporting back.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

28 3PurityPaulOR, MaxMetOK, MounjBrad and 25 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register